Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966493 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
A Phase 2 study of Persistent Corneal Epithelial Defect, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT05966493 is a Phase 2 study of Persistent Corneal Epithelial Defect that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 84 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT05966493, a Phase 2 study of Persistent Corneal Epithelial Defect, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG lufepirsen high dose
- DRUG lufepirsen low dose
Study Locations (20)
Florida
- Glaukos Investigative Site - Bradenton
- Glaukos Investigative Site - Fort Myers
- Glaukos Investigative Site - South Miami
California
- Glaukos Investigative Site - Petaluma
- Glaukos Investigative Site - Torrance
Colorado
- Glaukos Investigative Site - Colorado Springs
- Glaukos Investigative Site - Grand Junction
Missouri
- Glaukos Investigative Site - Kansas City
- Glaukos Investigative Site - Kansas City
Texas
- Glaukos Investigative Site - Houston
- Glaukos Investigative Site - San Antonio
Alabama
- Glaukos Investigative Site - Dothan
Georgia
- Glaukos Investigative Site - Atlanta
Indiana
- Glaukos Investigative Site - Carmel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2023-08-17 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05966493
The ClinicalTrials.gov registry entry for NCT05966493 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Persistent Corneal Epithelial Defect appearing as the primary indexed condition, and to 3 interventions - of which Vehicle is the first listed.
NCT05966493 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05966493 about?
NCT05966493 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED". This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.
What is the current status of trial NCT05966493?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2023-08-17. Estimated completion is 2025-12.
What conditions does trial NCT05966493 study?
This clinical trial studies the following conditions: Persistent Corneal Epithelial Defect.
What interventions are being tested in trial NCT05966493?
The interventions under investigation include: Vehicle (DRUG), lufepirsen high dose (DRUG), lufepirsen low dose (DRUG).
Who is sponsoring clinical trial NCT05966493?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05966493 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Persistent Corneal Epithelial Defect
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.